Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 610: Safety and PK of 10E8VLS and VRC07-523LS in Healthy Adults
NCT03565315Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 10E8VLS in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 3 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 3 days and 2 more. Started Jul 2018; status: terminated.
02
Drugs
10E8VLS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03565315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565315.